Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Program Official
Principal Investigator
Shahzad Siddique
Awardee Organization

Commonspirit Health Research Institute
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

CIRI Oncology Research Alliance

The CommonSpirit Health Research Institute (CSHRI) Oncology Research Alliance (CORA) seeks to continue to support and expand a community-based cancer research network, made up of community hospitals and cancer centers and incorporate best practices in enrolling patients to National Cancer Institute (NCI)sponsored cancer control, prevention, and care delivery clinical trials and other human subjects’ studies. The specific aims are: to increase enrollment in cancer control, prevention and care delivery clinical trials by providing access to a wide portfolio of high quality research studies that meet the needs of CORA’s various populations, annually accruing 10% of new cancer cases within the populations served by the network; and identify, design and implement Cancer Care Delivery Research (CCDR) that leads to improved models of care and translates to high-quality, value-based services throughout the oncology continuum. Applying CSHRI’s innovative, centralized and standardized organizational research model encompassing a network of geographically diverse community cancer programs, CSHRI will continue to provide the necessary resources for amplifying clinical trials across the country. CORA’s geographic reach and involvement with multiple distinct primary and sub-affiliates allow it to offer a wide portfolio of trials to large, established programs as well as small, rural sites and new regions that historically have had limited access to cancer clinical trials. Applying best practices from CORA to all current and new primary and sub-affiliates along with increased physician engagement will increase the number of patients screened and enrolled in clinical trials. Leveraging CommonSpirit Health’s (CSH) unique, well-positioned standard oncology electronic health records (EHRs), enterprise data warehouse, and analytics capabilities will continue to give CORA the depth of data and access to information needed to expand CCDR. CSH’s EHRs at CORA sites yield accessible data across the network that feeds into the data warehouse. CSH’s single network tumor registry database and EHR make CORA responsive to requests for data around patterns of care. Lastly, the advanced patient navigation, survivorship, and multidisciplinary conferences and disease site specific tumor boards already in place at all primary and sub-affiliate sites will support this research. Expanding to additional health systems and sites, and adding new investigators as opportunities arise will increase the number of patients that CORA can screen for enrollment in cancer clinical trials. CORA primary and sub-affiliates’ community outreach coordinators’ and navigators’ integrated efforts will be utilized to improve cancer control and prevention, detection, care delivery, and treatment for these populations. Continued growth of CORA’s community partner networks, translation support and nurse navigation training at all primary and sub-affiliate sites will help eliminate barriers to care.

Publications

  • Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15;130(10):1747-1757. Epub 2024 Jan 18. PMID: 38236702
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Nov 1;39(31):3522-3524. Epub 2021 Sep 23. PMID: 34554848